MUC-1 Recognition-Based Activated Drug Nanoplatform Improves Doxorubicin Chemotherapy in Breast Cancer.

Pilei Si,Jinjin Shi,Pei Zhang,Cao Wang,Haijun Chen,Xuefang Mi,Wenling Chu,Baoping Zhai,Wentao Li

DOI: https://doi.org/10.1016/j.canlet.2019.12.019

IF: 9.756

2019-01-01

Cancer Letters

Abstract:Tumor-targeted drug delivery systems with stimuli-response drug release have been increasingly used to improve the therapeutic efficacy of antitumor drugs. Here, we report a specific molecular recognition activation drug nanoplatform based on specially designed DNA sensor-capped doxorubicin (DOX)-loaded mesoporous silica nanoparticles (MSNs), designated as specific molecular recognition-activated nanoparticle (SMRAN). DNA sensors on the targeted nanoparticles can trigger DOX release through a conformational switch induced by MUC-1. This causes a significant difference in cell viability between breast cancer MCF-7 and normal breast Hs578bst cells (24.8% and 86.0%). In vivo experiments showed that the tumor volume was reduced 1.5-times in the SMRAN treatment group. Compared with that in the DOX group, due to significantly improved tumor accumulation and retention of DOX. The strategy of the MUC-1 activated drug delivery system is expected to provide a new perspective for clinical application.